Survival
Clinical, diagnostic and prognostic relevance of GATA3 in malignant pleural mesothelioma: a retrospective cohort study
BMC Cancer 2026 April 2 [Link] Alejandro Avilés-Salas, David Dávila Dupont, Alejandro Aranda-Gutierrez, Andrea Nallely Heredia-Jara, Enrique Caballé-Perez, Luis Cabrera-Miranda, Andrés F Cardona, José Lucio-Lozada, Cesar Castillo-Ruiz, Norma Hernandez-Pedro, Luis Corrales, Claudio Martin, Oscar Arrieta Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a poor prognosis and limited treatment options. Recently, GATA3 has emerged as a useful adjunct immunohistochemical marker, especially for non-epithelioid subtypes. Although…
Read MoreDynamic evaluation of the glycolytic determinants LDH-A and GLUT-1 enhances prognostic significance and their inhibition affects the growth of mesothelioma spheroids
Molecular Metabolism 2026 May [Link] Marika A Franczak, Federica Borea, Valentina Donati, Marta Aliprandi, Amir Avan, Valentina Doldi, Giulia Bononi, Kin Yip Tam, Carlotta Granchi, Ryszard T Smolenski, Paolo A Zucali, Filippo Minutolo, Godefridus J Peters, Elisa Giovannetti Abstract Energy metabolism plays a crucial role in determining the aggressiveness of cancer. In this study, we…
Read MorePhase 1/1b study of direct intratumoral injection of pleural mesothelioma of immunostimulant prior to surgical resection
The Journal of Thoracic and Cardiovascular Surgery 2026 March 24 [Link] Andrea S Wolf, Shubham Gulati, Komal Dolasia, Bailey Fitzgerald, Jorge Gomez, David Yankelevitz, Andres Salazar, Alexander M Tsankov, Thomas Marron, Raja Flores Abstract Objective: To evaluate the role of neoadjuvant injection of the viral mimic poly-ICLC (polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose) in patients with pleural mesothelioma…
Read MorePhase 1/1b study of direct intratumoral injection of pleural mesothelioma of immunostimulant prior to surgical resection
The Journal of Thoracic & Cardiovascular Surgery 2026 March 24 [Link] Andrea S Wolf, Shubham Gulati, Komal Dolasia, Bailey Fitzgerald, Jorge Gomez, David Yankelevitz, Andres Salazar, Alexander M Tsankov, Thomas Marron, Raja Flores Abstract Objective: To evaluate the role of neoadjuvant injection of the viral mimic poly-ICLC (polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose) in patients with pleural mesothelioma…
Read MorePhase 1/1b study of direct intratumoral injection of pleural mesothelioma of immunostimulant prior to surgical resection
The Journal of Thoracic and Cardiovascular Surgery 2026 March 24 [Link] Andrea S Wolf, Shubham Gulati, Komal Dolasia, Bailey Fitzgerald, Jorge Gomez, David Yankelevitz, Andres Salazar, Alexander M Tsankov, Thomas Marron, Raja Flores Abstract Objective: To evaluate the role of neoadjuvant injection of the viral mimic poly-ICLC (polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose) in patients with pleural mesothelioma…
Read MorePretreatment volume-based 18F-FDG PET/CT parameters as prognostic indicators in malignant peritoneal mesothelioma patients
Japanese Journal of Radiology 2026 March 21 [Link] Kazuhiro Kitajima, Kosuke Matsuda, Hiroyuki Yokoyama, Toshiyuki Minami, Akifumi Nakamura, Kozo Kuribayashi, Takashi Kijima, Koichiro Yamakado Abstract Objective: This study was conducted to examine relationships of pretreatment volume-based quantitative 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) parameters with overall survival (OS) in malignant peritoneal mesothelioma (MPeM) patients.…
Read MoreCytoreductive Surgery With or Without HITHOC for Pleural Mesothelioma: A Meta-analysis of Survival and Perioperative Outcomes
Annals of Surgical Oncology 2026 March 16 [Link] Lucas Monteiro Delgado, Rachid Eduardo Noleto da Nobrega Oliveira, Guilherme Franceschini Machado, Luiza Soares Guerra, Cauã de Toledo Corrêa, Mario Claudio Ghefter, Paulo Manuel-Pêgo Fernandes, Marcello Migliore, Ricardo Mingarini Terra, Paula Duarte D’Ambrosio Abstract Background: Pleural mesothelioma (PM) is a rare and aggressive malignancy with limited overall…
Read MorePivotal role of long non-coding RNA in the development of new therapeutic approaches for pleural mesothelioma
Discover Oncology 2026 March 12 [Link] Caroline Joseph Kiriacos, Dina M Elkahwagy, Manar Mansour Abstract Pleural mesothelioma is a rare aggressive tumor that affects the parietal layer of the pleura. It constitutes 90% of mesotheliomas. Usually, the diagnosis takes place 30 to 40 years after asbestos exposure. Thus, patients are diagnosed at a very late…
Read MoreHormonal Status May Contribute to Sex-Based Survival Differences in Epithelioid Peritoneal Mesothelioma
Annals of Surgical Oncology 2026 March 12 [Link] Kaelyn C Cummins, Olivia Sears, Elio R Bitar, Chengli Shen, Allan Tsung, Samantha M Ruff Abstract Background: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is central to treating patients with epithelioid peritoneal mesothelioma (EPM). Male sex is a negative prognostic factor in mesothelioma, but the reasons…
Read MoreAdvancing Rare Cancer Therapeutics: Osimertinib-Loaded Inhaled PLGA Nanoparticles for Mesothelioma Treatment
AAPS PharmSciTech 2026 March 4 [Link] Mural Quadros, Naveen Rajana, Vivek Gupta Abstract Despite advances in mesothelioma treatment, malignant pleural mesothelioma (MPM) continues to present a poor prognosis due to its aggressive progression and resistance to conventional therapies. Current treatment modalities, including surgery, chemotherapy, radiation, and immunotherapy, offer limited efficacy, with a five-year survival rate…
Read More
Skip to content